REGN Upgraded by Argus Research -- Price Target Announced at $85

Regeneron (REGN) shares fell 4% after expanding its alliance with Sanofi, with Sanofi paying $1B upfront and up to $7B in milestones for new antibodies. The deal leaves Dupixent profit-sharing terms unchanged, disappointing investors who expected better terms. Shares later recovered slightly to close down 2.9% at $736.56.

Regeneron Pharmaceuticals (REGN) reported early-stage trial results for ubamatamab, showing 73% efficacy in ovarian cancer patients but 90% adverse events. REGN plans a Phase 3 trial. GF Value™ suggests REGN is 19.9% undervalued at $726.86. GF Score™ is 88/100. Insiders sold $12.9M shares in 12 months.

Regeneron Pharmaceuticals (REGN) reported Phase 1/2 trial data for ubamatamab, an ovarian cancer therapy. While all 19 patients experienced adverse events, 73% of heavily pretreated patients showed partial responses. Regeneron plans a Phase 3 trial and FDA data submission.

Regeneron Pharmaceuticals reported initial Phase 1/2 trial data for its ovarian cancer therapy, ubamatamab. The company's stock initially rose but later declined. Regeneron is collaborating with Sanofi on the development.

Regeneron Pharmaceuticals (REGN) reported positive Phase 2 trial results for trevogrumab, showing it preserves muscle mass during weight loss. The stock is trading at $729.20, 19.6% below its GF Value™ of $907.43, indicating modest undervaluation. The company has a GF Score™ of 88, reflecting strong fundamentals, but insiders have been net sellers.

Sanofi and Regeneron have expanded their alliance with a $1 billion upfront payment. The collaboration focuses on developing and commercializing therapeutic products, including Regeneron-discovered antibodies targeting IL-13, IL-4, and IL-4Rα. Both companies issued forward-looking statements outlining potential risks and uncertainties.